Carriers of two copies of the loss-of-function CYP2C19*2 variant convert less clopidogrel into its active metabolite, resulting in diminished antiplatelet responses and higher cardiovascular event rates. To evaluate whether increasing the daily clopidogrel dose in poor metabolizers (PM) overcomes the effect of the CYP2C19 * 2 variant, we enrolled 18 healthy participants in a genotype-stratified, multi-dose, three-period, fixed-sequence crossover study. Six participants with the *1/*1 extensive (EM), *1/*2 intermediate (IM), and *2/*2 poor metabolizer genotypes each received 75 mg, 150 mg, and 300 mg each for 8 days. In each period, maximal platelet aggregation 4 hours post-dose (MPA4) and active metabolite area under the curve (AUC) differed among genotype groups (P < .05 for all). At day 8, PMs needed 300 mg daily and IMs needed 150 mg daily to attain a similar MPA4 as EMs on the 75 mg dose (32.6%, 33.2%, 31.3%, respectively). Similarly, PMs needed 300 mg daily to achieve active metabolite concentrations that were similar to EMs on 75 mg (AUC 37.7 and 33.5 ng h/mL, respectively). These results suggest that quadrupling the usual clopidogrel dose might be necessary to overcome the effect of poor CYP2C19 metabolism.
metabolite concentrations, which results in diminished antiplatelet responses and higher cardiovascular event rates. [6] [7] [8] The significantly diminished active metabolite concentrations, attenuated antiplatelet effect, and increased cardiovascular outcome rates in PMs led to placement of a Boxed Warning in the clopidogrel drug label for prescribers to consider alternative treatments or treatment strategies in PMs. 9 Dosing regimens to overcome the diminished responses have the potential to improve clinical outcomes for patients predicted by genotype to be likely clopidogrel non-responders. Administering clopidogrel loading doses of 600 mg or higher (without respect to genotype), instead of 300 mg, has become a common practice that has been shown to result in higher antiplatelet responses and improved outcomes. 10, 11 Similarly, in studies, higher maintenance doses lead to greater protection from stent thrombosis, although bleeding rates are also higher. Considering the redundancy in the metabolic activation pathway of clopidogrel, which includes CYP1A2, 2B6, 2C9, 3A4, and 3A5, in addition to CYP2C19, higher loading and maintenance doses may be able to compensate for the lower active metabolite exposures resulting from CYP2C19 poor metabolism. However, the optimal dose to normalize exposures and antiplatelet responses across CYP2C19 genotype groups has not been determined, despite the initiation of clinical trials designed to evaluate the clinical utility of higher clopidogrel doses. [12] [13] [14] [15] [16] [17] Targeting dose adjustments to those who are most likely to have reduced antiplatelet responses could improve outcomes and minimize the bleeding risks associated with nontargeted dose increases.
The objective of this prospective, CYP2C19 genotypestratified, dose-escalation study of clopidogrel was to determine whether increasing clopidogrel maintenance doses up to 300 mg daily increases active metabolite exposure and antiplatelet responses in subjects who are CYP2C19 IMs and PMs, providing evidence for the feasibility of dose-adjustment strategies to normalize the active metabolite and antiplatelet responses.
Methods

Subjects
Eighteen healthy, white, Amish men and women between the ages of 20 and 70 years who had participated previously in the Pharmacogenomics of Antiplatelet Intervention (PAPI) study were recruited. 8 Six subjects from each of the CYP2C19 genotype groups [*1/*1 (EM), *1/*2 (IM), and *2/*2 (PM)] were enrolled. EM and IM subjects were matched by age and sex to PM subjects. Subjects were excluded if the following were present: blood pressure >160/95 mmHg, malignancy, creatinine>2.0 mg/dL, AST or ALT > 2 times the upper limit of normal, hematocrit <32% or >50%, TSH < 0.4 or >0.5 mIU/L, history of bleeding disorder or gastrointestinal bleed, history of cardiovascular disease or type 2 diabetes, platelet count <150,000 or >500,000, surgery within 6 months, allergy to clopidogrel, breast feeding. All participants were healthy subjects who were not taking concurrent medications, and all nutritional supplements, including multivitamins, were discontinued at least 7 days prior to the initial study visit through the end of the entire study period. Subjects provided written informed consent. The protocol was approved by the University of Maryland, Baltimore Institutional Review Board and the FDA Research Involving Human Subjects Committee.
Study design
The trial was a prospective, open-label, multiple-dose, fixed-sequence crossover study. All subjects initially received clopidogrel 75 mg daily for 8 days (period 1). The dose of clopidogrel was increased in successive treatment periods to 150 mg daily for 8 days (period 2) and 300 mg daily for 8 days (period 3). There was a washout period between each treatment period of at least 7 days to allow platelet function to return to baseline; this washout period is commonly utilized for maintenancedose clopidogrel platelet function studies, consistent with platelet clearance. On the first day of each treatment period, subjects presented to the clinic and following baseline assessment of platelet function, the first dose of clopidogrel was administered under direct observation, after which blood samples were drawn for pharmacokinetic analysis and platelet aggregometry. Subjects were then discharged and instructed to take clopidogrel every day. Subjects returned to the clinic on day 8 of each treatment period, and platelet aggregometry was performed 4 hours after the last dose of each study period. Medication usage history and pill counts were performed to confirm adherence. All study procedures were carried out at the University of Maryland Amish Research Clinic in Lancaster, PA.
Endpoints
The primary endpoint was the difference in maximal platelet aggregation 4 hours post-dose (MPA4; units are a percentage) on day 8 of each treatment period (reflecting steady-state) between 75 mg and the higher doses within each genotype group. Absolute MPA4 was selected rather than inhibition of platelet aggregation (IPA) in an effort to minimize the possibility of carry-over effects from each treatment period. Secondary endpoints compared by genotype groups (using EMs as the reference) and dosing periods (using 75 mg as the reference) were as follows: MPA4 on day 1, relative IPA at 4 hours (IPA4) on days 1 and 8 (IPA4 ¼ [1 À MPA4 on day 8/MPA0 on day 1 Â 100]), area under the time-concentration curve (AUC 0-4 ) and maximal concentration (C max ) for clopidogrel active metabolite and parent compound on day 1 between 75 mg and the higher doses within each genotype group.
Genotyping
Genotyping of the known common loss-of-function CYP2C19*2 variant (rs4244285) was performed using TaqMan 1 SNP genotyping assays (Applied Biosystems, Foster City, CA). Subsequent to the study, genotyping of the CYP2C19*17 variant (rs12248560) and the CES1 G143E (rs71647871) SNP were performed using TaqMan 1 SNP genotyping assays (Applied Biosystems).
Sampling
Blood samples were drawn at the beginning of each period prior to administering the clopidogrel to assess baseline platelet aggregation. Following the first dose, blood samples were drawn at 0.25, 0.5, 1, 2, and 4 hours for pharmacokinetic analyses. Blood samples for pharmacokinetic analysis of parent clopidogrel were collected in tubes containing EDTA, whereas blood samples for active metabolite were collected in tubes containing EDTA and the thiol protecting group (derivatizing agent) 2-bromo-3 0 -methoxyphenone (MPB; final concentration 2 mM in the 6-mL volume). Pharmacokinetic samples were drawn following the first dose because the active metabolite has a short half-life and does not accumulate with repeated dosing. In each period, blood samples for platelet aggregometry were drawn prior to dosing, 4 hours after the first dose, and 4 hours following the last dose (on day 8).
Pharmacodynamic Assessments
Platelet function was assessed by optical aggregometry. Venous blood was drawn into 3.2% citrate-anticoagulated tubes (Becton-Dickinson, Franklin Lakes, NJ). Platelet rich plasma was prepared from whole blood and platelet counts adjusted to 200,000 platelets/mL with platelet poor plasma. Platelet poor plasma was prepared individually for each participant using his own blood sample. Initially the specimen was spun at 880 rpm for 10 minutes to obtain a sample of platelet rich plasma (approximately two-thirds of the sample), then the remaining one-third of the sample was centrifuged at 3,300 rpm for 15 minutes at room temperature to obtain the platelet poor plasma.
Platelet aggregation was assessed in a PAP8E Aggregometer (Bio/Data Corporation, Horsham, PA) after stimulating samples with ADP 20 mmol/L. Measurements were performed in duplicate and averaged to minimize variability.
Pharmacokinetic Assessments
Plasma concentrations of clopidogrel and its active metabolite were simultaneously assessed using a validated, rapid, and sensitive ultra HPLC-MS/MS assay, developed for this study as previously described, with a clopidogrel calibration range of 0.01-50 ng/mL and active metabolite calibration range of 0.1-150 ng/mL. 18 The assay accuracy ranged from À11.7% to À2.37% with within-run precision less than 1.1% for clopidogrel and from À6.78% to À2.23% with within-run precision of less than 1.2% for the active metabolite. 18 
Statistical Analyses
Pharmacokinetic parameters for clopidogrel active metabolite and parent compound were estimated using standard non-compartmental methods with WinNonlinEnterprise v5.2, Pharsight Corp. (Mountain View, CA). Plasma concentrations less than the lower limit of quantitation (LLOQ) were reported as zero and included as zero in calculation of PK parameters. The PK parameters calculated were C max , T max , t 1/2 , and AUC 0-4 .
Descriptive statistics were calculated as medians and interquartile ranges (IQR), arithmetic means and standard deviation, or geometric means and coefficient of variation. Differences in platelet aggregation and pharmacokinetics among the three genotype groups were compared using the Kruskal-Wallis test. Pairwise differences in platelet aggregation and pharmacokinetic parameters between 75 mg and each of the higher doses and between genotypes were compared using the Wilcoxon signedrank test. Deviations from proportionality between dose and platelet aggregation or pharmacokinetic parameters (log-transformed) were evaluated using a mixed model with period and subject as random effects fit for each genotype stratum, or with a genotype Â treatment interaction term. Geometric mean ratios (GMR) of MPA4, C max , and AUC 0-4 (active metabolite and parent compound) were calculated for each of the higher doses relative to 75 mg to assess the magnitude of change in exposure or response. The relationship between active metabolite exposure and response was further evaluated using linear regression. All statistical analyses were 2-sided at the 0.05 significance level, except GMR calculations used the typical 90% confidence interval (CI). The study was designed to enroll six subjects in each genotype group to provide 80% power to detect a 20% absolute mean difference in MPA4 between 75 mg and each of the higher doses, assuming two-tailed a ¼ 0.05 and a standard deviation for the difference of 15%. Statistical analyses were performed using SAS version 9.2 or JMP 9.0 (Cary, NC).
Results
Disposition and Baseline Characteristics
All 18 subjects completed all three periods of the protocol. The study population's mean (SD) age was 42 (10) years, 33% were women, and the mean (SD) body mass index was 27.7 (4.7) kg/m 2 . One pretreatment sample from a PM was hemolyzed during the 150 mg period and was excluded from analysis. One IM and two EMs were carriers of the CYP2C19*17 variant, which is expected based on high linkage disequilibrium between the CYP2C19*17 and CYP2C19*2 variants (D 0 ¼ 1, r 2 ¼ 0.07) in the Amish population. 19 There were no adverse bleeding events in any of the participants. Mean pretreatment MPA did not differ by genotype in any of the treatment periods, and although a numeric decrease in pretreatment MPA from study period 1 to study period 3 was noted in EMs, no significant period effect was observed (e.g. for ADP 20 mmol/L, 75 mg period, EM 72%/IM 72%/PM 74%, P ¼ .96; 150 mg period EM 64%/ IM 74%/PM 67%, P ¼ .36; 300 mg period, EM 59%/IM 71%/PM 70%, P ¼ .13).
Platelet Aggregation
Platelet aggregation results (MPA4 and IPA4) on day 8 of all three clopidogrel dosing periods are shown in Figure 1 by CYP2C19 genotype. At each dose level, MPA4 on day 8 differed significantly among the CYP2C19 genotype groups such that PMs had the lowest antiplatelet responses (i.e. highest MPA4; Table 1 ). Relative to EMs, MPA4 was approximately 70% higher in PMs (P ¼ .02 in each dose period) and 30% higher in IMs (P > .05 for each dose period). The magnitude of the genetic effect was consistent across all dose levels.
Compared to 75 mg, increasing the daily clopidogrel dose resulted in greater platelet inhibition in all genotype groups ( Figure 1 and Table 1 ). The incremental effect of increasing doses was similar across genotype groups (genotype Â dose interaction P ¼ .5). Relative to 75 mg, 150 mg decreased MPA4 by 21% in EMs, 12% in IMs, and 20% in PMs, while 300 mg decreased MPA4 by 39% in EMs, 32% in IMs, and 41% in PMs. The dose-response relationship was not linear in any of the genotype groups; quadrupling the dose resulted in less than a doubling of response. Treatment of PMs with 300 mg daily allowed them to achieve levels of platelet inhibition similar to 75 mg in EMs (the reference dose and genotype; geometric mean MPA4 31% [95% CI 24- EMs). The results for MPA4 following the first dose on day 1 showed trends consistent with those on day 8 described above (not shown). IPA4 was more variable than MPA4. The findings for IPA4 were similar to MPA4, with IPA4 tending to be progressively lower in IMs and PMs compared to EMs. At a clopidogrel dose of 300 mg, there was no significant difference in IPA4 among genotypes.
Pharmacokinetics
Clopidogrel active metabolite and parent compound pharmacokinetics (C max and AUC 0-4 ) on day 1 of all three dosing periods are shown in Figure 2 by CYP2C19 genotype. Consistent with the findings for antiplatelet responses, active metabolite C max and AUC 0-4 differed significantly among the genotype groups at all dose levels ( Table 2) . PMs had active metabolite exposures that were approximately half that of EMs (P < .01 at all dose levels). Active metabolite exposures in IMs were similar or only modestly reduced compared to EMs (average of 10% lower across dosing periods; P > .05 at all dose levels). The overall median T max was 1 hour and the overall median t 1/2 was 0.5 hours for the active metabolite; neither of these parameters differed by genotype in any of the dosing periods (not shown).
Compared to 75 mg daily, increasing the clopidogrel dose resulted in higher active metabolite exposure (C max and AUC 0-4 ) in all genotype groups (Table 2) . Consistent with the findings for antiplatelet response, with increasing dose the increase in C max was less than dose proportional. Relative to 75 mg, 150 mg resulted in a 19% increase in active metabolite C max and 45% increase in AUC 0-4 , on average across the genotype groups, while administering the quadruple 300 mg dose resulted in a 69% increase in C max and 124% increase in AUC 0-4 . At the 150 and 300 mg dose levels, the absolute exposure increases tended to be greatest in EMs and IMs compared to PMs, but the relative increases in exposure were of similar magnitude across genotypes (genotype Â dose interaction P ¼ .71 for C max and P ¼ .56 for AUC 0-4 ). PMs treated with 300 mg daily attained an AUC 0-4 similar to 75 mg in EMs (geometric mean 36 ng h/mL [95% CI for 300 mg in PMs vs. 33 ng h/mL [95% CI [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] for 75 mg in EMs). Similar findings were observed for C max .
Clopidogrel parent compound exposures were highly variable. Consistent with the findings for the active metabolite, parent compound exposures increased with each successive dose increase (Table 2) . Parent compound exposures did not differ according to CYP2C19 genotype, and the magnitude of change following each dose increase was similar across the genotype groups.
Exposure-Response Relationship
Active metabolite exposure was moderately correlated with antiplatelet responses in each dosing period as shown in Figure 3 . Similar findings were observed for C max (not shown).
Discussion
Previous studies have demonstrated that individuals with high platelet reactivity after receiving standard doses of clopidogrel exhibit higher rates of cardiovascular events relative to those who have lower platelet reactivity. 20, 21 Targeted strategies to minimize heterogeneity in antiplatelet responses, either by way of dose-adjustment or selecting patients for more potent antiplatelet therapies, have the potential to improve treatment outcomes. Common loss-of-function variants in CYP2C19 account for approximately 12% of the variation in residual platelet reactivity after standard-dose clopidogrel and are associated with poorer cardiovascular outcomes; 8 CYP2C19
PMs consistently have low active metabolite exposure and antiplatelet responses. In this study, we demonstrated that increasing clopidogrel doses in CYP2C19 PMs overcomes the diminished antiplatelet responses and that active metabolite concentrations correlate with antiplatelet responses. Specifically, daily doses of 300 mg were necessary in PMs to match the exposure and antiplatelet response observed with standard 75 mg doses in EMs. The presence of increasing active metabolite concentrations with increasing doses suggests the possibility that other CYP enzymes, including CYP1A2, 2B6, 2C9, 3A4, and 3A5, which have been implicated in the conversion of clopidogrel to its active metabolite, take over the role of oxidizing the pro-drug sequentially to its active metabolite, particularly in CYP2C19*2 homozygotes (PMs) who lack all CYP2C19 activity.
2,3
Results from prior studies that tested the effectiveness of higher daily dosing of clopidogrel in IMs have been mixed. Simon et al 12 studied the effect of a 600 mg clopidogrel loading dose followed by 4 days of a 150 mg maintenance dose in prospectively genotyped healthy subjects. The investigators found that the higher-dose regimen provided greater platelet inhibition and higher clopidogrel active metabolite concentrations in IMs, although not to the levels observed in EMs who received the standard 300 mg loading dose and four days of clopidogrel 75 mg. Similarly, other studies that used a 150 mg maintenance dose in IMs have shown that such a dose adjustment did not, on average, reduce platelet reactivity to the levels observed with standard 75 mg dosing in EMs 14, 15, 22, 23 or with prasugrel, 24 despite providing additional platelet inhibition. The findings of our study are qualitatively consistent with these prior studies insofar as escalating clopidogrel doses helps increase the active metabolite concentrations and reduce platelet reactivity, and suggest that IMs require at least double the approved daily clopidogrel dose to achieve similar levels of platelet inhibition to EMs. Importantly, our study shows that PMs taking the 300 mg daily dose were able to achieve platelet inhibition on par with EMs taking the 75 mg dose. In contrast, in ELEVATE-TIMI 56, the only other study in which a 300 mg maintenance dose has been studied, this high-dose therapy was not able to lower on-treatment platelet reactivity in PMs to levels seen in EMs. 23 Also, in ELEVATE-TIMI 56, IMs receiving the 225 mg dose attained platelet reactivity measures that were similar to EMs taking 75 mg daily, whereas we found that 150 mg resulted in IM responses that were similar to EMs. While the doses identified in each study may differ somewhat, both our study and ELEVATE-TIMI 56 suggest that modifying the dose enhances response, and both studies report a nonlinear relation between increasing dose of clopidogrel and decreases in platelet aggregation at higher doses in the IM and PM groups, which is consistent with previous pharmacokinetic studies. 25 The differences between our findings may stem from the methodology. In particular, ELEVATE-TIMI 56 enrolled subjects with cardiovascular disease who were receiving aspirin and assessed on treatment platelet reactivity index determined through phosphorylation status of VASP and VerifyNow P2Y12, while we enrolled healthy subjects and evaluated ex vivo platelet aggregometry in response to ADP.
Of particular relevance to ongoing and future trials, both studies suggest that 150 mg daily may not be the most suitable dose to evaluate in response-or genotypeguided antiplatelet trials that include PMs. Our findings show that at least 150 mg daily may be suitable for IMs, but PMs may require doses of 300 mg of clopidogrel daily to reduce platelet aggregation and to attain concentrations of the active metabolite seen in EMs taking 75 mg daily. To the extent that CYP2C19 IMs and PMs are enriched among the poor responders as determined by platelet function testing, available data suggest clopidogrel doses higher than 150 mg daily may be necessary to reduce events in patients who appear to have resistance to clopidogrel therapy based solely on markers of platelet function. Importantly, the long-term safety with clopidogrel doses higher than 75 mg daily has not been established. Moreover, the potential for accumulation of non-active metabolites and additional drug-drug interactions that are not observed at lower clopidogrel doses must be considered. As such, these findings and the findings of ELEVATE-TIMI 56 raise an important issue about whether dose-adjusted strategies should be considered for PMs at all when alternative drugs that do not have a major CYP2C19 effect are available.
Interestingly, although differences in active metabolite concentrations were observed across genotype groups in our study, parent compound concentrations did not significantly differ by genotype. These findings are consistent with the known metabolism of clopidogrel, in which approximately 85% of the parent compound is converted to non-active metabolites independent of CYP2C19, and only a minority is metabolized to the active metabolite by CYP2C19-dependent and -independent pathways. 26 Carboxylesterase 1 (CES1) is the primary enzyme responsible for converting clopidogrel into inactive carboxylic acid metabolites, while CYP1A2, 2B6, 2C9, 2C19, 3A4, and 3A5 all contribute to the formation of the active metabolite. 27 This complex metabolic process, with overlapping pathways of clopidogrel activation, has led to questions regarding the importance of any single metabolic enzyme in the production of the active metabolite. Moreover, drug-drug interaction studies using CYP2C19 inhibitors (e.g. proton pump inhibitors), and studies evaluating CYP2C19 genotype, have not all demonstrated an association between CYP2C19 and clinical outcomes in clopidogrel-treated patients. 4, 28 However, numerous pharmacokinetic and pharmacodynamic studies have established CYP2C19 genotype as an important factor in the activation and antiplatelet effects of clopidogrel. 26 Our findings provide additional data supporting the importance of CYP2C19 genotype in the activation of clopidogrel, and demonstrate that high doses of clopidogrel can overcome CYP2C19 metabolic deficiency, likely through activation of the parent compound via other metabolic pathways. Future studies are warranted to identify the mechanism by which parent clopidogrel is converted to its active metabolite in poor metabolizers.
Our study has several limitations that are worth noting. First, the study was conducted in a small sample of healthy participants with no history of cardiovascular disease, and these participants were not taking aspirin. Thus, the study provides data which may not reflect the biological milieu of a patient on dual antiplatelet therapy following an acute event. However, this tailored design allowed us carefully to study the effect of escalating doses of clopidogrel in each genotype group, which were prospectively selected and matched for potential confounders, using a clopidogrel-specific response measure. Also, the magnitude of the pharmacokinetic and response differences between the genotype groups was similar to that observed in patients with cardiovascular disease taking aspirin. 23, 29 Second, we evaluated only maintenance doses of clopidogrel and not loading doses that are commonly used in perioperative period for patients undergoing PCI. In addition, pharmacokinetic parameters were assessed following administration of only the first dose of clopidogrel; therefore, the possibility of a change in steady-state pharmacokinetic properties with high-dose clopidogrel administration cannot be dismissed. Third, the study was not designed to determine whether higher doses in IMs or PMs would carry similar risk to the 75 mg dose in EMs for bleeding or other complications, which are a potential concern given the higher dose of parent drug. Nevertheless, the results from our analyses of the active metabolite concentrations and platelet aggregation suggest that PMs treated with 300 mg daily would be at no increased risk for bleeding complications than would EMs treated with the approved 75 mg dose. Fourth, we only enriched for the *2 loss of function variant in CYP2C19 and not other common or rare loss or gain of function CYP2C19 variants. In the current investigation one IM and two EMs were carriers of the CYP2C19*17 gain-offunction variant. We do not expect the presence of this variant in some subjects to be a major source of confounding in the current analysis since stratified and adjusted analyses in a larger sample from the Amish population have previously shown that the CYP2C19*17 variant has a minimal effect on clopidogrel related traits in this population. 19 Additionally, a functional variant in CES1 is associated with better clopidogrel response in this and other populations. 30 Only one IM was a carrier for the CES1 variant in the current investigation, thus we were not able to fully evaluate the effect of this variant. Fifth, our study was restricted to Caucasians, although we know of no data to support that the CYP2C19*2 enzyme functions differently by race. Finally, our primary outcome in this study of healthy participants was platelet aggregation and not a clinical measure. Although platelet aggregation may be of limited utility for prospective doseadjustment and in medically managed populations, 31, 32 it is a well-established way to assess the effects of antiplatelet therapy, and it is correlated with clinical outcomes in patients undergoing PCI. 20, 21 Whether using quadruple daily doses of clopidogrel in PMs will result in better outcomes than the standard dose therapy will require a very large, prospective clinical trial. It is also unclear whether chronically higher exposures to the parent drug would present other non-bleeding safety concerns.
In conclusion, consistent with other studies, we show that IMs and PMs administered clopidogrel have higher levels of platelet aggregation and lower concentrations of the clopidogrel active metabolite than do EMs. We observed increasing active metabolite concentrations as the clopidogrel dose was increased from 75 to 150 to 300 mg in each of the three genotype groups, with a similar relationship observed for reductions in ex vivo platelet aggregation, although, the magnitude of the changes were less than proportional to the dose. A dose of 300 mg daily appears to be required to normalize active metabolite concentrations and antiplatelet responses in PMs. Thus based our findings and those of Mega et al, 23 the 150 mg dose that is being studied in ongoing, genotype-guided outcomes trials, 17 may not be adequate to overcome reduced CYP2C19 metabolism, particularly in PMs.
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